Salt Lake City, Utah-based Myriad Genetics is reporting that the results of its Phase 2 follow-on study of its Flurizan treatment for patients with mild Alzheimer's disease demonstrates significant benefits. The firm, which develops molecular diagnostic products, and is developing molectular therapeutic products, said that the lead investigator for its Phase 2 trial found that participants taking Flurizan demonstrated a substantial benefit over other dose groups in the study in the area of cognition, memory loss, global function and activities of daily living. The firm said that it is now enrolling patients in a global Phase 3 trial, in Italy, France, Germany, Spain, Sweden, Switzerland, the United Kingdom, Netherlands, the United States, Belgium, Canada and Denmark. Myriad's Flurizan attacks Amyloid beta-42, the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease.
Top NewsWednesday, July 19, 2006
Myriad Announces Positive Study Results On Alzheimer's Drug